Plain-English translation of NCT07174583 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called , which is designed to fight certain lung cancers and neuroendocrine tumors. The medication works by targeting a protein called DLL3 that appears on cancer cells. Researchers will test whether the medication works better alone or when combined with other immune-boosting drugs.
Small-cell lung cancer and related neuroendocrine tumors are aggressive cancers that often come back after standard chemotherapy. This trial exists to see if targeting the DLL3 protein with this new antibody drug could give patients a more effective treatment option.
You likely qualify if…
You likely don't qualify if…
The trial has two main phases. In the first phase, researchers will gradually increase the dose of the medication to find the safest and most effective dose, testing it alone and in combination with other drugs. In the second phase, more participants will receive the doses that worked best. Throughout the trial, you will visit the clinic for treatment infusions, blood tests, tumor imaging scans, and monitoring for side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States